

Identification of Novel Hits Against SARS-CoV-2 Main Protease through Virtual Screening of Human Metabolites

Rajarshi Roy¹, Md Fulbabu Sk¹, **Omprakash Tanwar**^{†2}, Parimal Kar^{1,*}

¹Department of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore 453552, Madhya Pradesh, India.

²Department of Pharmacy, Shri G. S. Institute of Technology and Science, Indore 452003, Madhya Pradesh, India

*Corresponding author Email: parimal@iiti.ac.in, † Presenting author, op0816@gmail.com

A joint project by SGSITS Indore and IIT Indore




Presented by **Dr. Omprakash Tanwar**
Assistant professor, S.G.S.I.T.S., Indore, India



Graphical abstract

Title: Identification of Novel Hits Against SARS-CoV-2 Main Protease through Virtual Screening of Human Metabolites



Human Metabolites

In-silico Metabolomics screening


Best Hits

Abstract

- The present research covers the identification of novel hits against the 3-chymotrypsin-like proteases (3CLpro) protein of SARS-CoV-2 using virtual screening (VS) and Molecular Dynamic (MD) simulations. After VS and MD simulations, the top 8 virtual hits displayed a docking score varying between ~ -11 to ~ -14 kcal/mol. MS simulations further confirmed their binding modes and supported the results. The best hit (HMDB0132640) possesses the docking score (glide score) of -14.06 kcal/mol, and MM-GBSA binding free energy, of -18.08 kcal/mol. The other compounds were selected and found to possess drug-like ADME properties. The other virtual hits include HMDB0127868, HMDB0134119, and HMDB0125821, and they showed favorable contributions from the intermolecular electrostatic and van der Waals interactions. To the best of our knowledge, we are the first to identify novel compounds from a pool of human metabolite databases against SARS-CoV-2 Main Protease that was unexplored before about developing novel antiviral drugs
- **Keywords:** SARS-COV-2; Main Protease; Human metabolites; Virtual Screening; Molecular Dynamics; Free Energy.





Introduction

- Novel coronaviruses (SARS-CoV-2) infection leads to the development of COVID-19 which if severe, results in death due to cytokine storm in lungs and other tissues.



Introduction

- According to National Health Service (NHS) UK, there are three small molecules available for the treatment of COVID-19, however they have many side effects which limits their use.




Introduction

- Thus there is a need of effective small molecules that can reduce the viral load effectively and do less harm to the human body.
- **The metabolomics** has been shown to be one of the promising techniques in drug discovery [1].
- The metabolomics is an emerging technology, and very soon, it will be an essential part of precision medicine [2].
- The Human Metabolome Database (**HMDB**) is a freely downloadable database of indigenous metabolites, natural compound metabolites and drug metabolites.
- Herein, we have screened the molecules available at HMDB against 3CLpro (main protease, or **Mpro**) of SARS-CoV-2 to find some potential metabolites and to develop new therapies to tackle viral infections.

Methodology and Work Flow


- Database collection and virtual screening setup
- Molecular Weight based filtering of database
- Coarse Screening (HTVS/SP docking) against 3CLpro of SARS-COV-2 (**PDB ID- 6LU7**)
- Extensive sampling Screening (XP docking)
- Hit validation using MD simulation and energy calculation
- Final Selection of best compounds.



Results and Discussion

Figure 1: Structures of Best 8 hits

Ribbon representation of COVID19 3CL^{pro} complexed with the inhibitor, shown in ball and stick representation. The different part of 3CL^{pro} is shown in different color, i.e., Green: Domain I, Cyan: Domain II, Blue: Domain III, Brown: Inter-domain connecting loop, and Red: Ligand molecules. The top 8 molecules which are screened by the virtual screening workflow are shown in 2D illustration



Results and Discussion

- Energetics: Different components of docking scores obtained from the Glide-XP docking scheme.

Lead molecule	Molecular Weight	G-Score ^a	Glide-lipo ^b	Glide-hbond ^c	Glide-evdw ^d
Ligand1 (HMDB0132640)	568.657	-14.060	-4.160	0.000	-39.543
Ligand2 (HMDB0030665)	622.706	-12.399	-2.859	-0.339	-61.108
Ligand3 (HMDB0128347)	573.59	-12.151	-2.359	-0.800	-48.830
Ligand4 (HMDB0134117)	598.64	-11.724	-2.228	-0.769	-36.536
Ligand5 (HMDB0125819)	424.444	-11.534	-3.702	-0.160	-47.989
Ligand6 (HMDB0127868)	492.564	-11.134	-2.904	-0.887	-29.007
Ligand7 (HMDB0134119)	598.64	-11.119	-3.060	-0.430	-40.603
Ligand8 (HMDB0125821)	394.418	-11.051	-3.369	-0.480	-44.484

^a Glide Score (kcal/mol), ^b Lipophilic term derived from hydrophobic grid potential, ^c hydrogen bonding term in GlideScore, ^d Van der Waals energy

Results and Discussion

- Eight best hits were selected based on their interaction pattern, Molecular Dynamic simulation stability pattern of complexes and binding energies.






Figure 2; A, B The time evolution of root means square deviation (RMSD) of backbone atoms of 3CL^{pro}-complex relative to their respective initial coordinates. **C, D** The root mean square fluctuations (RMSFs) of C α atoms for all eight 3CL^{pro}-ligand complexes

Figure 2: Energy components (kcal/mol) for human metabolites' binding affinity against 3CL^{pro}. ΔE_{vdW} and ΔE_{elec} are change in van der Waals and electrostatic energy components in the gas phase; ΔG_{pol} and ΔG_{np} are changes in polar and non-polar solvation energy components. $T\Delta S_{MM}$, configurational entropy contribution and ΔG_{bind} , total affinity.


Results and Discussion: More about Hit-1

Hit-1 (HMDB0132640):




Babchi


- Hit-1 is one of the predicted metabolites of Isobavachalcone which is obtained from the seeds of *Psoralea corylifolia* (Babchi). Isobavachalcone has a proven effective against **papain-like protease** (PLpro) of SARS-CoV [1] and mPro of Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) [2].



Docking pose of Hit-1



2D Plot of Hit-1



Superimposed Hit-1 and Reference Ligand

- Kim DW, Seo KH, Curtis-Long MJ, Oh KY, Oh JW, Cho JK, Lee KH, Park KH, J Enzyme Inhib Med Chem. 2014 Feb;29(1):59-63
- Jo S, Kim H, Kim S, Shin DH, Kim MS. Chem Biol Drug Des. 2019 Dec;94(6):2023-2030. .

Conclusions and Future Plans

- This study concludes that the natural compound metabolites can play a promising role in managing the SARS-COV-2 infection.
- We screened the human metabolite database-4.0 against main protease (M^{pro}) of SARS-COV-2 and selected the top 17 lead molecules for further validation.
- Finally 8 compounds were selected based on 100ns long molecular dynamics simulations and the free energy calculation using the MM/GBSA scheme.
- We found that one of the metabolites of **isobavachalcone** (Ligand1: HMDB0132640) binds very well (-18.08 kcal/mol) to 3CLpro of SARS-COV-2.
- Overall, these metabolites have a good chance of being developed as possible COVID19 protease inhibitors.
- In future we plan to synthesize and test these derivatives for further validation

Publication and Acknowledgments

- **This article has been published as;** Roy, R., Sk, M.F., Tanwar, O. et al. Computational studies indicated the effectiveness of human metabolites against SARS-Cov-2 main protease. *Mol Divers* (2022). <https://doi.org/10.1007/s11030-022-10513-6>.
- This work was partially supported by the Department of Science and Technology, Govt. of India (grant number DST/NSM/R&D_HPC_Applications/2021/03.18). RR thanks the Indian Institute of Technology Indore for financial assistance. MFS would like to thank the Department of Science and Technology, Govt. of India, for providing a doctoral fellowship under the INSPIRE fellowship scheme (DST/INSPIRE Fellowship/2017/IF170145).
- **Dr. Omprakash Tanwar** from wish to acknowledge the support of **Dr. Rakesh Saxena**, Director Shri G.S. Institute of Technology and Science, Indore, Madhya Pradesh, India for providing sufficient computational facilities to accomplish this work.